Elevai LabsELAB
ELAB
About: Elevai Labs Inc is a California-based physician-dispensed skincare company with a focus on modernizing aesthetic skincare. It has commercialized ELEVAI Exosomes a next-generation, patent-pending technology used in its ELEVAI flagship products.
Employees: 18
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
163% more capital invested
Capital invested by funds: $86.9K [Q2] → $228K (+$141K) [Q3]
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more funds holding
Funds holding: 4 [Q2] → 8 (+4) [Q3]
12.43% more ownership
Funds ownership: 0.8% [Q2] → 13.23% (+12.43%) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for ELAB.
Financial journalist opinion
Based on 5 articles about ELAB published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it completed a strategic reorganization.
Neutral
GlobeNewsWire
2 days ago
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it plans to effectuate a strategic reorganization effective on December 20, 2024. This reorganization will include changing the Company's name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. After this reorganization, the Company will continue to trade on The Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “ELAB.” The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024.
Neutral
GlobeNewsWire
2 weeks ago
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
Elevai Skincare Expands into Hair Care with Cutting-Edge Scalp and Hair Health System. Root Renewal System Features Exclusive Technologies and Science-Driven Formulations.
Neutral
GlobeNewsWire
4 weeks ago
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (Elevai" or the "Company") announced today it will implement a 1-for-200 reverse stock split (“Reverse Stock Split”) of its common stock, which will be effective at midnight on November 27, 2024.
Neutral
GlobeNewsWire
4 weeks ago
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has withdrawn the previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), as a result of notice from the Depositary Trust Company (“DTC”) that due to logistical issues, DTC would not be able to accept the tenders of Common Stock.
Neutral
GlobeNewsWire
1 month ago
CORRECTION - Elevai Labs Inc.
NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc. (NASDAQ: ELAB), please note that in the headline and first paragraph, the financial results are from the company's third fiscal quarter of 2024, not the second fiscal quarter as previously stated; as such, the header over the first bullet list should note the financial results as being from the three and nine months ended September 30, 2024, rather than the three and six months ended June 30, 2024 as previous stated.
Neutral
GlobeNewsWire
1 month ago
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation. Elevai Enfinity™ Clinical Trials Showcase Breakthroughs in Skin Firmness, Tone, and Wrinkle Reduction, Reinforcing Leadership in Aesthetic Innovation.
Neutral
GlobeNewsWire
1 month ago
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock.
Neutral
GlobeNewsWire
2 months ago
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (“FDA”) in 2025 Muscle wasting is a common side effect of popular GLP-1 weight-loss medications, with no current approved treatments.
Neutral
GlobeNewsWire
2 months ago
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl
Charts implemented using Lightweight Charts™